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Abstract: Recombinant human activated protein C (rhAPC) was developed to reduce excessive 
coagulant and inflammatory activity during sepsis. Basic and clinical research has suggested 
these pathways contribute to the pathogenesis of this lethal syndrome and are inhibited by 
rhAPC. Based in large part on the results of a single multicenter randomized controlled trial, 
rhAPC was first approved in 2001 by the US Food and Drug Administration (FDA) as adjunc-
tive therapy in septic patients with a high risk of death. This was followed closely by approval 
in Europe, Australia, and New Zealand. At the original FDA review of rhAPC, concerns were 
raised as to whether a confirmatory trial should be done before final regulatory approval because 
of concerns that rhAPCs bleeding risk might outweigh its potential benefit during clinical use. 
Since 2001, continuing basic and clinical research has further elucidated the complex role 
activated protein C may have in both adaptive and maladaptive responses during sepsis. Moreover, 
subsequent controlled trials in other types of septic patients and observational studies appear to 
support earlier concerns that the benefit-to-risk ratio of rhAPC may not support its clinical use. 
This experience has prompted additional trials presently underway, to define whether treatment 
with rhAPC as it was originally indicated in septic patients with persistent shock, is safe and 
effective. Until such trials are complete, physicians employing this agent must carefully consider 
which patients may be appropriate candidates for rhAPC administration.
Keywords: rhAPC, treatment, sepsis
Introduction
Septic shock is a major cause of morbidity and mortality in intensive care units and 
its incidence is increasing.1–4 While excessive release of host inflammatory mediators 
(eg, cytokines, prostaglandins) is closely associated with the pathogenesis of sepsis, 
increased host coagulant activity has been implicated as well. Microvascular throm-
bosis not only disrupts organ perfusion and function, but it may also stimulate further 
inflammatory mediator release and injurious processes such as apoptosis.5–8 Both 
preclinical and clinical studies have suggested that this excessive coagulant activity 
results in part from depletion or depression of endogenous anticoagulant systems.8 
One system central to normal coagulant homeostasis is the protein C (PC) system. 
Reductions in endogenous protein C and its active form, activated protein C (APC), 
have been associated with worsened outcome in sepsis.9–13 Based in large part on this 
association, recombinant human APC (rhAPC) was developed for use in patients with 
severe sepsis.
In contrast to a long list of other immunomodulators developed for sepsis, rhAPC 
was the first one reported to significantly improve survival in a single phase III Biologics: Targets & Therapy 2009:3 392
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multicenter trial: the Recombinant Human Activated Protein C 
Worldwide Evaluation in Severe Sepsis (PROWESS) study.14 
During the regulatory approval process questions were raised 
about the consistency of its effect in this trial, its mechanism 
of action and its safety profile. All of these concerns were 
addressed by the manufacturer and as a result, the US Food 
and Drug Administration (FDA) approved rhAPC for clinical 
use. Based on a significant relationship noted in the original 
trial between severity of disease (ie, Acute Physiology and 
Chronic Health Evaluation II Score) and the beneficial effect 
of rhAPC on mortality rates, use was restricted to patients 
with severe sepsis and a high risk of death. Furthermore, 
the FDA requested that the manufacturer of rhAPC conduct 
additional randomized controlled trials (RCTs) testing the 
effects of the agent in septic adults with a low risk of death, 
in pediatric patients, and in patients receiving prophylactic 
heparin. These were subgroups which had not been tested 
or where rhAPC appeared to show no benefit, or possible 
harmful trends.
rhAPC has now been in use clinically for almost 
eight years. During this time growing data from basic 
research has further defined the potential effects of rhAPC. 
In addition, the results of the RCTs requested by the FDA 
as well as clinical surveys assessing the use of rhAPC are 
available. The purpose of the present article is to review 
the growing insights this experience provides regarding the 
potential benefits and risks associated with use of rhAPC 
in sepsis.
Function and structure  
of activated protein C
Protein C is a vitamin K-dependent protein that normally 
circulates in a free state. In the setting of increased 
coagulant activity, thrombin (T) cleaves PC and generates 
APC. Formation of APC is increased 10,000-fold when 
thrombin is bound to thrombomodulin (TM), present on 
the endothelial surfaces of both large and small vessels.15 
This conversion is increased 20-fold further when pro-
tein C is bound in a Ca2+-dependent reaction by endothelial 
protein C receptor (EPCR) adjacent to the thrombin-
thrombomodulin (TTM) complex.15,16 EPCR is a trans-
membrane protein with a structure similar to the major 
histocompatibility class1/D1 family of molecules.15,17,18 
APC then complexes to protein S and inactivates factor 
Va and VIIIa to prevent further thrombin formation and 
coagulation.19
While anticoagulation with APC may be beneficial, its 
binding to EPCR also results in proteolytic activation of 
protease activated receptor-1 (PAR-1), providing alternative 
mechanisms for potential benefit in sepsis.20–23 The cleavage 
of PAR-1 exposes a tethered ligand that in turn stimulates 
G-protein mediated activation of mitogen activated protein 
kinase (MAPK) cascades.24 While thrombin can also bind 
to PAR-1, it produces inflammatory and apoptotic effects 
as opposed to APC-cleaved PAR-1, which elicits protective 
cell signaling responses.25,26
APC consists of a Gla domain necessary for EPCR 
binding, followed by two epidermal growth factor 
(EGF) domains, and finally a serine protease domain.27 
The active site for inactivation of Va and VIIIa by APC 
resides in the serine protease domain on two surface 
loops.17,28–33 While the position of the site necessary for 
PAR-1 activation is unclear, mutant deletion studies 
show it is distinct from the anticoagulant site.34–36 
In genetically engineered animals, improved survival 
following lipopolysaccharide (LPS) challenge required 
intact enzymatic activity of APC, EPCR, and PAR-1.37 
Furthermore, a recombinant APC variant with normal 
PAR-1 signaling but reduced anticoagulant activity 
improved survival with LPS challenge in mice similar 
to wild-type protein.37
APC and anticoagulation in sepsis
During infection, stimulation of monocytes, macrophages 
and endothelial cells by microbial toxins and host inflam-
matory mediators causes release of tissue factor.38 This 
results in a procoagulant state which is aggravated by sepsis 
related depression of counter regulatory anticoagulant 
mechanisms including the PC system.9,10,12,13,39,40 Septic 
patients have a reduction in endogenous PC, APC, and 
protein S, which may be due to decreased production by the 
liver or by degradation by neutrophil elastase.41 In addition, 
soluble forms of EPCR and TM released from injured 
endothelial cells bind to APC and competitively inhibit 
its uptake by the intact cellular proteins.39,42 Finally sepsis 
induced downregulation of EPCR and TM can further 
decrease endogenous APC generation.39
Analysis of PC levels in patients from the PROWESS 
trial showed an association between PC deficiency and 
death. Severe PC deficiency was associated with increased 
odds of death at 28 days as compared to subjects without PC 
deficiency. Furthermore, increased PC levels were associ-
ated with better outcome.11 Administration of rhAPC during 
sepsis decreased pro-coagulant markers (eg, prothrombin 
fragment and thrombin generation) and increased anticoagu-
lant ones (eg, plasminogen, antithrombin and protein C).43 Biologics: Targets & Therapy 2009:3 393
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Perhaps as a consequence, rhAPC infusion increased the 
rate of bleeding.14
Potential cytoprotective effects 
of APC in sepsis
Although the anticoagulation effects of rhAPC were believed 
important for its benefit in the PROWESS trial, two other 
antithrombotic agents (ie, anti-thrombin III and tissue factor 
pathway inhibitor), were not beneficial in phase III sepsis 
trials.44,45 This finding and others have suggested that the 
observed benefit of rhAPC in septic patients may have been 
related to mechanisms possibly mediated by PAR-1.22,46,47 
These nonanticoagulant mechanisms, now under study 
and collectively referred to as cytoprotective ones, include 
anti-inflammatory and antiapoptotic activities and endothelial 
barrier stabilization.
APC has been shown to have several effects on 
monocytes, endothelial cells, and neutrophils that could 
be anti-inflammatory ones. Either in LPS-stimulated 
monocytic cell lines or in monocytes from septic patients, 
APC 1) inhibits nuclear factor-kappaB (NF-κB) and the 
downstream pro-inflammatory cytokines NF-κB upregulates, 
2) inhibits macrophage inflammatory protein-1α release and 
3) stimulates production of the anti-inflammatory cytokine 
interleukin-10 (IL-10).48,50,51 In endothelial cells, APC 
1) inhibits NF-κB binding to DNA, 2) suppresses tumor 
necrosis factor (TNF)-mediated expression of the adhesion 
molecules vascular cell adhesion molecule (VCAM), 
intercellular adhesion molecule (ICAM), and E-selectin, 
and 3) reduces E-selectin-dependent leukocyte rolling.49,52,53 
Finally, APC inhibits IL-8, antithrombin, and C5a-mediated 
neutrophil chemotaxis.54 Consistent with such in vitro find-
ings, in vivo APC inhibition increased inflammatory cytokine 
levels in Escherichia coli-challenged baboons55 while rhAPC 
treatment in rats reduced leukocyte adherence to intestinal 
endothelial cells and improved microvascular perfusion.56 In 
normal human volunteers challenged with intratracheal LPS, 
rhAPC reduced pulmonary neutrophil recruitment.57 Finally, 
in the PROWESS trial itself, rhAPC treatment was associated 
with reduced IL-6 levels over time.43
Apoptosis of lymphocytes and endothelial cells may 
also contribute to the pathogenesis of sepsis and evidence 
suggests that APC can suppress this process via EPCR and 
PAR-1.6,7,58,59 Treatment of endothelial cells with APC inhibits 
the pro-apoptotic calreticulin gene and upregulates the anti-
apoptotic A1 Bcl-2 homologue and inhibitor of apoptosis 
protein-1 (IAP-1).60 In brain endothelial cells, APC prevents 
ischemia mediated apoptosis by inhibiting p53 suppressor 
protein and reducing caspase-3 activation.61 In a murine E. coli 
sepsis model, APC treatment reduced apoptotic proteins 
p21 and p53.62 Also APC via PAR1/sphingosine-phosphate 
(S1P), inhibited the endothelial cell expression and secretion 
of TNF-related inducing ligand (TRAIL) in a mechanism 
involving increased levels of early growth response factor 
(EEGR)-1 and of phosphorylated ERK 1/2.63
APC stabilization of endothelial cell integrity and 
vascular permeability via EPCR and PAR-1 may also be 
beneficial during sepsis.64 APC-mediated EPCR/PAR-1 
binding stimulates sphingosine kinase-1 (SphK-1) to form 
S1P.65,66 In turn, S1P can activate the sphingonase-1-
phosphate receptor (S1P1), a G-protein-coupled receptor, 
which results in cortical cytoskeleton rearrangement and 
stabilization.67–69 With endotoxin challenge, S1 administra-
tion prevented lung edema in the dog, and increased tissue 
permeability in the mouse.70,71
Evolving clinical experience 
with rhAPC
In 2001, results from the Phase III Activated Protein C 
Worldwide Evaluation in Severe Sepsis (PROWESS) trial 
were published in The New England Journal of Medicine.14 
The reported findings were striking with the agent producing 
a statistically significant 6% absolute reduction in sepsis 
related mortality. Furthermore, while bleeding, a likely 
complication associated with rhAPC, was increased with 
treatment this did not reach statistical significance. This 
report raised great hope in health care workers treat-
ing patients with sepsis.
Further analysis of the trial by the US FDA officials and 
an FDA advisory panel however, raised several questions 
regarding the promising results of the PROWESS trial. First, 
while rhAPC did show an overall significant beneficial effect, 
this appeared to occur primarily in patients with a high risk 
of death as measured with the Acute Physiology and Chronic 
Heath Evaluation Score (APACHE II). This score was used 
to stratify patients for primary analysis in PROWESS, and, 
as determined by the FDA, was most effective in classify-
ing patients by risk of death and by the likelihood of benefit 
from rhAPC.14,72 Importantly however, the decision to treat 
with rhAPC in the trial itself was not based on this score. 
Instead, APACHE II scores were determined retrospectively 
using the most extreme values obtained over the 24-hour 
period before the drug was administered. Second, while the 
risk of hemorrhage with treatment as compared to placebo 
during the overall study did not reach significance (3.5 vs 
2.0, respectively; p = 0.06), serious hemorrhage during drug Biologics: Targets & Therapy 2009:3 394
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infusion, was significantly increased with rhAPC (0.2 vs 0.1; 
p = 0.02). An ongoing open label trial at the time supported 
concern regarding this bleeding risk.73 While other questions 
also arose regarding changes in patient selection criteria and 
treatment preparation during the trial, the most concerning 
issues for members of the advisory panel were whether 
it was clear which patient population would benefit from 
rhAPC, and whether the potential risk of hemorrhage would 
outweigh that benefit during clinical use.74 These questions 
about the safety and efficacy of rhAPC in the PROWESS trial 
prompted half the FDA advisory panel members (10 of 20) 
to vote that the agent undergo additional phase III testing.74 
Nonetheless, the FDA approved rhAPC, but restricted its use 
to septic patients with a high risk of death. It also directed the 
manufacturer to perform phase IV studies to clarify its effects 
in adult septic patients with a low risk of death, pediatric 
patients, and in combination with prophylactic heparin.
Unfortunately, since a confirmatory trial was not originally 
performed in the population the agent was prescribed for, early 
questions raised by the PROWESS trial have persisted.75–85 
At present, answers to those questions can only be sought from 
controlled trials that have been conducted subsequently, and 
in the increasing number of uncontrolled studies assessing the 
clinical experience published since rhAPC’s approval. While 
such data lack the clarity a randomized control trial might 
offer, the combined experience to date with rhAPC supports 
concerns that the benefit from rhAPC may not be as great as 
originally reported, and the risk of hemorrhage is very real 
and likely increases during clinical use.
Assessment of rhAPC’s benefit  
since the PrOweSS trial
One can try to assess the effect of rhAPC on survival in sepsis 
(ie, its beneficial effect) since the PROWESS trial in at least 
two ways. First, one can compare its effects to placebo treated 
patients in subsequent controlled trials. Second, one can 
compare survival rates in patients receiving rhAPC in uncon-
trolled studies to patients in the original PROWESS trial after 
attempting to control for severity of sepsis or risk of death. 
The APACHE II score is employed primarily for this purpose 
here since, as outlined above, it provided the basis for primary 
analysis in PROWESS and was the best predictor of death and 
of the likelihood of benefit with rhAPC in the FDA’s review 
of this trial.14,72 Furthermore, differentiation of the effects of 
rhAPC based on the APACHE II score is common in both 
controlled and uncontrolled studies (Table 1 and 2).14,73,86–90 
In addition, mean organ injury scores are presented when 
reported. Two points of caution are necessary. First, injury 
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severity scores such as these have not been developed for the 
purpose of assessing the effectiveness of treatments across 
subgroups and may have major limitations in this setting. 
Second, even after accounting for severity of illness, differ-
ences in other variables may weaken comparisons between 
controlled and uncontrolled trials.
Placebo-controlled trials
Two subsequent placebo-controlled trials have assessed 
the effect of a similar regimen of rhAPC to the one used in 
PROWESS in patients with sepsis. The Drotrecogin Alfa 
(activated) for Adults with Severe Sepsis and Low Risk 
of Death (ADDRESS) was a placebo-controlled double 
blind multicenter RCT of rhAPC in septic patients with a 
low risk of death (APACHE  25 in the United States or 
single organ failure in Europe)91 (Table 1). In ADDRESS, 
investigators could at their discretion include patients with 
an APACHE II score  25 or multiorgan failure if they 
felt the patient was still at low risk of death. In contrast to 
PROWESS, in which APACHE II scores were determined 
retrospectively, in ADDRESS, APACHE II scores (or other 
measures of risk) were calculated prospectively. Patients had 
to start therapy within 48 hours of first organ dysfunction 
and exclusion criteria were similar to PROWESS. While the 
overall estimated low mortality rate of the targeted population 
required enrollment of 11,444 subjects to show efficacy if 
one existed, the trial was halted after enrolling only 2,640 
due to futility. Overall 28-day mortality was not significantly 
different with rhAPC compared to placebo (18.5% vs 17.0%, 
respectively; p = 0.34) (Table 1). As designed, 88% of all 
enrolled patients had an APACHE II score  25. After strati-
fication by APACHE II, 28 day mortality rates with rhAPC 
were not statistically different when compared with placebo 
whether scores were 25 (16.9% vs 16.0%, respectively; 
p = 0.55) or 25 (29.5% vs 24.7%, respectively; p = 0.34) 
(Figure 1). Notably, the absence of increased survival 
in patients with APACHE II  25 (324 total patients) in 
ADDRESS was very different from the improvement noted in 
this subgroup in PROWESS (Odds ratio of survival [95% CI]: 
0.9 [0.8, 2.1] vs 1.7 [1.3, 2.3], respectively). Although this 
difference is highly concerning, it must be recognized that 
control mortality rate in ADDRESS patients was also lower 
based on investigators original estimate of enrollees’ risk of 
death (Figure 1).75,81,82
Severe sepsis is a leading cause of death in infants 
and children, with a hospital mortality rate of 13%.92 Beyond 
supportive care and antibiotics, there are no approved 
adjunctive therapies. Despite the difficulties associated with 
pediatric investigations, and based on the reported benefits of 
rhAPC in PROWESS, a trial with this agent was conducted 
in children with sepsis. The Researching Severe Sepsis 
and Organ Dysfunction in Children: a Global Perspective 
Table 2 Summary of uncontrolled studies
Nonsurvivors/Total number of 
patients
 
Author
 
Name
Dates of 
enrollment
 
28 days
Hospital or ICU 
discharge or 90 daysa
Age 
(year)*
 
APACHE II score*
Organ injury 
score*
Tanzi102 NAb 5/02–11/03 NA 265/599 57 NA 3.0 (1.1)
Vincent73c ENHANCE 3/01–1/03 601/2378 NA 59 (17) 19 (7) 2.7 (1.1)
Kübler100 NA 4/03–11/05 NA 118/302 45 (18) 25 (10) NA
Spriet101 NA 7/03–1/06 17/23 11/23 59 25 3.0 (4)
Levi87d XPRESS 12/02–8/05 580/1927 NA 59 (17) 24 (7) 3.0 (1.2)
Kanji99 NA 3/03–2/04 NA 118/261 56 32 (26,36)e 3.4 (1.0)
Bertolini97 NA 8/03–3/06 NA 310/668 58 NA NA
Wheeler104 NA 11/01–12/02 NA 115/274 57 (18) 27 (9) 2.9 (1.1)
Ridley88 NA 12/02–11/05 NA 164/351 61.8 23 (7) 3.3 (1.0)
Vincent90 NA 7/03–9/04 184/436 224/436 NA 24 (8) 3.1 (1.0)
Rowan89 NA 12/02 NA 398/1079 59 (16) 22 (7) 3.3 (0.9)
Taylor103 NA 1/01–12/04 32/99 NA 64.6 28 (8) NA
Gentry86 NA 1/02–12/05 NA 26/73 57 24 NA
Decruyenaere98 BOOST 12/03–10/03 31/97 41/97 61.4 (19) 25 (9) 3.4 (1)
Notes: aAll studies assessed hospital discharge except the ones by Kubler and Bertolini that assessed iCU discharge and by Decruyenaere that assessed 90 days; bNot available; 
cBolded studies were provided support by the manufacturer of rhAPC (eli Lilly and Company); dCompared prophylactic heparin treatment to placebo in critically ill patients, 
all of whom were receiving rhAPC; einterquartile range. *Means ± standard deviation.Biologics: Targets & Therapy 2009:3 396
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(RESOLVE) was an open-label placebo-controlled trial in 
pediatric patients93 (Table 1). Children with sepsis were 
enrolled within 48 hours of first organ dysfunction or within 
24 hours of dual cardiac and respiratory dysfunction. Severity 
of sepsis for a pediatric population was great (ie, all patients 
required mechanical ventilation and vasopressors). While the 
primary endpoint was a composite time to complete organ 
failure resolution (CTCOFR) score, 28 day mortality was a 
secondary one. Compared to placebo, rhAPC did not alter the 
CTCOFR score (6% vs 6%; p = 0.72) nor did it improve mor-
tality (17.5% vs 17.2%, respectively; p = 0.93) (Figure 1).
Since PROWESS, two controlled trials not requested by 
the FDA have also compared the effects of rhAPC to placebo: 
one in patients with acute lung injury (ALI), some of whom 
had sepsis,94 and another in septic patients who had completed 
a 96-hour course of rhAPC, but in whom shock persisted95 
(Table 1). In patients with ALI, compared to placebo, rhAPC 
did not decrease the number of ventilator-free days, the 
primary outcome (Median [IQR]: 19 [14, 22] vs 19 [0, 24], 
respectively; p = 0.78). Sixty-day mortality, a secondary 
outcome, was the same between the two groups (13.5%) 
(Figure 1). Unfortunately, the effect of rhAPC in the subgroup 
of patients with sepsis as the cause of ALI was not reported. 
In the second study, a total of 193 patients who had already 
completed a 96-hour infusion of rhAPC, but who were still in 
shock, were randomized to placebo or an additional 72-hour 
rhAPC infusion (Table 1). Extended rhAPC infusion did 
not resolve vasopressor-dependent shock, the primary end-
point, more quickly than controls (34% vs 40%, respectively; 
p = 0.42). Compared to placebo, 28-day mortality was higher 
with rhAPC but not significantly different (32.3% vs 39.8%; 
p = 0.28) (Figure 1). Importantly, while fifty-three patients 
(27.5%) had protocol violations, most commonly due to 
discontinuation of study drug, the study group assignments 
of these patients were not identified. Furthermore, although 
it was reported that prothrombin and thrombin times did not 
differ between groups, partial thromboplastin times (PTT), 
which can be increased with rhAPC, were not reported. If PTT 
data were available for review by clinicians, it is possible that 
more patients in the treatment group had therapy stopped early 
based on increased PTT values and concern over bleeding.
Uncontrolled phase IIIB  
or IV studies
The extended evaluation of rhAPC in the treatment of severe 
sepsis (ENHANCE) trial was a single arm, multinational 
Figure 1 The effect of recombinant human activated protein C (rhAPC) on the odds ratio of survival in controlled trials comparing this agent to placebo. Patients are stratified 
into subgroups with acute physiology and chronic health evaluation ii scores (APACHe ii)  or 25 where data were available since this score was employed by the US Food 
and Drug Administration (FDA) in its approval of rhAPC. Notably, over the more than 5000 patients studied, the only subgroup showing benefit was the 421 patients with 
APACHe ii  25 receiving rhAPC in the original PrOweSS trial.
Notes: aPhase ii study results from the subgroup of patients testing a 96-hr infusion of rhAPC (24 mg/kg/hr), the regimen employed in later control trials and approved by the FDA.
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study designed to further examine the safety and efficacy of 
rhAPC in adult patients with sepsis73 (Table 2). Although an 
open label study, inclusion and exclusion criteria and time 
to treatment (within 48 hours of organ dysfunction) were the 
same as in PROWESS. It was considered a phase IIIB trial 
because it was initiated before final regulatory approval of 
rhAPC. A total of 2,378 patients were treated with rhAPC 
and the overall 28-day mortality rate (25.3%) was not dif-
ferent than in PROWESS (24.7%). However, in ENHANCE 
patients with APACHE II  25, mortality was higher than in 
similar patients in PROWESS (36.7% vs 30.9%) (Figure 2). 
Despite this difference, the mortality rate in this subgroup 
from ENHANCE was still lower than in control patients 
from PROWESS (43.7%). Also, when stratified by number 
of organs injured, the mortality rates in PROWESS and 
ENHANCE were similar (Figure 3). Based on these latter 
points, some would argue that the efficacy of rhAPC in 
PROWESS was reproduced in ENHANCE.
A potential benefit with earlier treatment (24 hours) 
with rhAPC in ENHANCE was not borne out after 
multivariate logistic regression analysis adjusted for possible 
covariates (p = 0.08). In spite of this fact, the European 
Medicines Agency (EMEA) amended its indication for 
rhAPC to start treatment within 24 hours,96 although this 
was questioned.84
The Xigris and Prophylactic Heparin Evaluation in Severe 
Sepsis (XPRESS) trial was a double-blind randomized 
international trial in adult patients receiving rhAPC for severe 
sepsis with a high risk of death (APACHE II  25, or 2 
organ failures) (Table 2).87 It was a phase IV trial requested 
by the FDA to compare the effects of prophylactic heparin 
therapy (either low molecular weight heparin [LMWH] 
40 mg q24h or unfractionated heparin [UFH] 5000 units 
q12h) to placebo in patients receiving rhAPC. As such, all 
patients received rhAPC. In this population of septic patients, 
compared to placebo, 28-day mortality rate was lower 
with heparin treatment overall, although not significantly 
different (31.9% vs 28.3%; p = 0.08). The incidence of 
thromboembolic complications was equivalent between the 
two groups, however ischemic strokes were less common in 
the heparin group (0.3% vs 1.3%; p = 0.02). Furthermore, 
in patients on heparin prior to randomization, mortality rate 
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Figure 2 Comparison of mortality rates and the average APACHe ii score in the subgroup of patients receiving rhAPC with APACHe ii scores  25 from the PrOweSS trial 
to mortality rates and average APACHe ii scores in patients receiving rhAPC in subsequent uncontrolled trials. Mortality rates at 28 days are shown in the upper panel A) and at 
hospital or intensive care unit discharge or 90 days in the lower panel B). results from the subgroup of patients shown from the PrOweSS trial provided the basis for approval 
of rhAPC. in almost all uncontrolled studies, mortality rates have been higher and average APACHe ii scores lower than in the subgroup in PrOweSS with APACHe ii  25.
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was significantly higher in those randomized to placebo 
compared to those who continued heparin (35.5% vs 26.9%; 
p = 0.005), in spite of similar baseline characteristics for age, 
disease severity, and comorbidities.
Although the XPRESS study was designed to enroll 
patients with APACHE II scores  25, more than half the 
patients (53.7%) had scores less than 25. Despite mean 
APACHE II scores that were very similar in patients 
receiving rhAPC in PROWESS (n = 851) and XPRESS 
(n = 1927) (24 ± 8 vs 24 ± 7, respectively), 28-day mortality 
rate was higher in patients in XPRESS (n = 1927) (30.1% 
vs 24.7%, respectively). In addition, compared to patients 
receiving rhAPC in PROWESS with APACHE II  25 
(mean 31 ± 5, n = 414), overall mortality in XPRESS (ie, 
both placebo and heparin patients), was only marginally 
different (31.9% vs 30.1%, respectively) despite having 
a substantially lower mean APACHE II score (Figure 2). 
Of note, the mean organ injury score was higher in XPRESS 
than in PROWESS (3.0 ± 1.2 vs 2.7 ± 1.1, respectively) and 
mortality rate in XPRESS was lower than in PROWESS 
control patients with APACHE II scores  25.
Other uncontrolled studies
In addition to ENHANCE and XPRESS, there have been a 
series of reports regarding clinical experience with rhAPC 
following completion of PROWESS and approval of the 
agent86,88–90,97–104 (Table 2). Some have been conducted with 
support from the manufacturer of rhAPC (n = 5) and others 
have been independent studies (n = 7). While all have 
reported mortality rates in septic patients receiving rhAPC, 
the measures have varied (eg, 28 day, 90 day, hospital or 
intensive care unit [ICU] mortality).
Most studies provided APACHE II score data which can 
be compared to PROWESS. As noted above, approval of 
rhAPC was based on its apparent effectiveness in patients 
in PROWESS with APACHE II scores  25. The mean 
(± standard deviation [SD]) APACHE II score in these 
patients was 31 (± 5) and 28-day and hospital mortality 
rates were 30.9% and 36.7%, respectively. It is therefore 
noteworthy that while the reported mean APACHE II scores 
in subsequent uncontrolled trials have been consistently 
less than 31, mortality rate (28 day or ICU or hospital) has 
been the same or greater than in PROWESS in most studies 
(Table 2) (Figure 2). It is possible that the APACHE II score 
does not accurately reflect underlying severity of disease. 
Frequently, the mean number of organs injured was higher 
in uncontrolled trials compared to patients with APACHE II 
scores  25 in PROWESS. However, even if one further 
controls for this variable by stratifying patients based on 
number of injured organs, mortality rates with rhAPC in those 
studies presenting such data have in almost all subgroups 
been greater than in PROWESS with the exception of those 
60
2 3 4 5
a
a
a
a
a a
a a a a
a
a
N= 271 370 20 51 147 80 214 470 31 176 47 115 119 645 157 60 100 29 31 457 17 45 29 40
50
40
30
20
10
0
Study
2
8
-
D
a
y
 
o
r
 
h
o
s
p
i
t
a
l
 
m
o
r
t
a
l
i
t
y
 
r
a
t
e
 
(
%
)
PROWESS Trial
Uncontrolled studies
Number of injured organs
Bernard 14
Bernard 14
Bernard 14
Tanzi 102
Vincent 73
Vincent  73
Kanji 99
Ridley 88
Tanzi 102
Kanji 99
Ridley 88
Decruyenaere 98
Vincent 73
Tanzi 102
Kanji 99
Ridley 88
Decruyenaere 98
Bernard 14
Vincent 73
Tanzi 102
Kanji 99
Ridley 88
Decruyenaere 98
Decruyenaere 98
Figure 3 Comparison of mortality rates (28 day or hospital) in subgroups of patients receiving rhAPC stratified by number of injured organs in the original PROWESS trial 
and subsequent uncontrolled studies. in almost all cases, mortality rates have been higher in subgroups of patients with similar numbers of injured organ in later uncontrolled 
studies compared to PrOweSS.
Notes: a28-day mortality.Biologics: Targets & Therapy 2009:3 399
Use of recombinant human activated protein C (rhAPC) in severe sepsis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
from ENHANCE14,73,88,99,102 (Figure 3). It should be noted 
that some uncontrolled studies reported that rhAPC use was 
associated with mortality rates, which although higher than in 
PROWESS, was less than predicted rates or rates in matched 
nonrandomized untreated patients.88,90
Assessment of rhAPC’s bleeding risk 
since the PrOweSS trial
While the benefit reported with rhAPC in PROWESS has not 
appeared as great during subsequent clinical experience, the 
bleeding risk has persisted and possibly increased. As with 
benefit, one can examine later placebo-controlled trials as 
well as uncontrolled studies to assess this potential problem 
with rhAPC, keeping in mind the caution necessary with 
such comparisons.
Placebo-controlled trials
Despite exclusion criteria in PROWESS designed to reduce 
the risk of hemorrhage with rhAPC, compared to placebo, 
treatment was associated with increases in serious bleeding 
both during infusion (2.4% vs 1.0%; p = 0.02) and over the 
28-day follow up period (3.5% vs 2.0%; p = 0.06) (Table 3 
and Figure 3). Intracerebral hemorrhage (ICH) was not sig-
nificantly different with treatment as compared to placebo 
(0.2% vs 0.1%, respectively; p = 0.6). Employing similar 
exclusion criteria to PROWESS, the incidence of serious 
bleeding in ADDRESS was increased with rhAPC compared 
to control in patterns very similar to PROWESS (2.4% vs 
1.2% during infusion [p = 0.02] and 3.9% vs 2.2% over the 
28-day follow-up [p = 0.01]) (Figure 4). The incidence of 
ICH however, was not statistically different (0.5% vs 0.4%, 
respectively; p = 0.79). Post-hoc analysis from ADDRESS 
data found that for patients who had undergone surgery 
within the past 30 days and had single organ dysfunction, 
compared to placebo, rhAPC was associated with higher 
28-day (20.7% vs 14.1%; p = 0.03) and in-hospital (23.4% 
vs 19.8%; p = 0.26) mortality rates. This group also had 
a higher rate of bleeding than placebo during infusion 
(10.3% vs 5.1%; p = 0.01) and the 28-day follow-up period 
(10.9% vs 6.1%; p = 0.03). Based on a similar trend in 28-day 
mortality rate in this same subgroup in PROWESS (24% vs 
16%, respectively; p = 0.60), the FDA issued a drug warn-
ing for patients with single organ dysfunction and recent 
surgery.105
The RESOLVE trial also employed exclusion criteria 
similar to PROWESS to reduce the risk of hemorrhage93 
(Table 3). Although there was no difference in overall serious 
bleeding events comparing placebo and rhAPC treatment 
during the 28-day study period (6.8% vs 6.7%, respectively; 
p = 0.97), there were numerically more instances of ICH 
bleeding with rhAPC during infusion (5 [2.1%] vs 1 [0.4%]; 
p = 0.22) and over the 28-day study period (11 [4.6%] 
vs 5 [2.1%]; p = 0.13) (Figure 4). Based on this finding 
in combination with the lack of efficacy of treatment in 
RESOLVE, the FDA issued a warning about the use of 
rhAPC in children.106
In the trial testing the effects of rhAPC in patients with 
ALI, compared to placebo treatment, rhAPC was associated 
with an increase in the incidence of serious bleeding over the 
28-day study period but this was not significant (8.1% vs 
3.5%; p = 0.58)94 (Table 3). In the trial testing extended use 
of rhAPC, bleeding during the initial 96 h of rhAPC treatment 
was not reported. Following this initial infusion period, 
compared to placebo, rhAPC was associated with increases 
in total (3.2% vs 1.0%; p = 0.3) and serious bleeding 
events (1.1% vs 1.0%; p = 1.0), although not significantly. 
The incidence of treatment discontinuation due to bleeding 
was not reported.
Uncontrolled phase IIIB  
or IV studies
The ENHANCE trial employed exclusion criteria similar to 
PROWESS.73 It was therefore concerning that the incidence 
of serious bleeding and ICH during rhAPC infusion (3.6% 
and 0.6%, respectively) and over the 28-day study period 
(6.5% and 1.4%, respectively) in ENHANCE was substan-
tially higher than in PROWESS (Table 3) (Figure 5).
The XPRESS trial employed package labeling to define 
patients eligible for enrollment. Compared to PROWESS, 
in both groups in XPRESS (rhAPC with either placebo or 
prophylactic heparin), the incidence of ICH during infu-
sion was higher (0.3%), as was the incidence of serious 
bleeding (4.6%) and ICH (0.9%) over the 28-day study 
period (Table 3) (Figure 5). Considering those patients in 
XPRESS not receiving heparin (ie, rhAPC and placebo, 
n = 955), the incidence of serious bleeding and ICH were 
higher than in PROWESS both during infusion (2.5% 
serious bleeding and 0.3% ICH) and over the 28-day study 
period (5.2% serious bleeding and 0.7% ICH).
Other uncontrolled studies
In most other uncontrolled studies assessing the use of rhAPC 
in sepsis, patients were reported to have been treated based on 
package labeling.73,87,91,93–95 Despite the potential for bleeding 
with the agent, one of these studies provided no information 
on the incidence of this complication.90 In the majority of the Biologics: Targets & Therapy 2009:3 400
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remaining studies, the incidence of serious bleeding events 
and of ICH in particular were higher than in PROWESS either 
during infusion or the entire period of follow-up Table 3) 
(Figure 5).73,86–89,97–99,101–104
Efficacy vs bleeding risk with rhAPC
The efficacy noted with rhAPC in PROWESS has not been 
reproduced in subsequent studies. Neither of the later con-
trolled trials in septic patients that employed the same regi-
men of rhAPC as PROWESS (ie, ADDRESS and RESOLVE) 
noted any significant benefit with treatment regardless of 
the underlying severity of disease. Across these three trials 
(enrolling approximately 5,000 patients), only one subgroup 
from one study demonstrated benefit (APACHE II scores  25 
from the PROWESS trial). This subgroup included only 414 
patients receiving rhAPC (17% of all patients receiving the 
agent in controlled trials). Notably, the later ADDRESS trial 
(n = 2,639 patients) also enrolled patients with APACHE II 
scores  25 (where investigators deemed them to be at low 
risk of death) but failed to reproduce the finding of efficacy. 
In fact, the treatment effect in ADDRESS was on the side 
of harm, opposite and different from the effect of rhAPC in 
PROWESS (Figure 1). This is more concerning since, dif-
ferent from PROWESS, the decision to treat in ADDRESS 
was actually based on calculation of an APACHE II score as 
would be done clinically. Prompting further questions about 
the efficacy of rhAPC in clinical practice, mortality rates 
from repeated uncontrolled studies have been consistently 
higher and APACHE II scores lower than in the PROWESS 
subgroup providing the basis for the agent’s original approval. 
Furthermore, although the mean number of injured organs 
have frequently been lower in these uncontrolled trials than 
in the PROWESS subgroup, after stratification, across this 
variable when this has been possible, mortality has tended 
to be higher. While this difference may relate to variation in 
administration of rhAPC (eg, increased treatment time or 
Figure 4 The effect of rhAPC on the odds ratio of a serious bleeding event or an intracerebral hemorrhage during drug infusion or over 28 days in controlled trials comparing this 
agent to placebo. Similar to PROWESS, in almost all cases, rhAPC was associated with a significant increase in the risk of hemorrhage or had an effect on the side of harm.
Notes: aSBe, serious bleeding event; bDuring infusion of rhAPC or placebo; cDuring the 28-day study period; diCH, intracerebral hemorrhage.
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patients with bleeding precautions during clinical use) and 
does not constitute proof of harm, it is worrisome.
While the apparent efficacy of rhAPC in PROWESS 
has not been reproduced, an increased risk of bleeding has 
been confirmed in controlled trials and documented at even 
higher rates in clinical use. Why this risk appears more pro-
nounced than during the original PROWESS trial is likely 
multifactorial. For example, investigating rhAPC in a larger 
number of control patients in the ADDRESS trial was neces-
sary to document the agent’s risk in surgical patients. Also, 
during controlled trials that are designed primarily to show 
the efficacy of an agent, exclusion criteria are frequently 
applied that minimize the occurrence of adverse events. 
During clinical use of an agent, such exclusion criteria may 
not be applied as rigorously and the incidence of adverse 
events may be expected to increase.107 Members of the FDA 
advisory panel considering rhAPC were concerned that 
unless the strict exclusion criteria related to bleeding were 
rigorously applied in clinical use, there would be a greater 
incidence of bleeding with this therapy. Yet when rhAPC 
was approved by the FDA, many of the exclusion criteria 
related to baseline bleeding risks in the PROWESS trial were 
labeled as “warnings” in the package insert. This labeling 
has allowed physicians to weigh the risks vs benefits of 
administering rhAPC to patients at high risk for bleeding. 
However, if these bleeding risks had instead been catego-
rized as “contraindications” such consideration would have 
been discouraged based on the package insert.
The possible problem associated with the present labeling 
of rhAPC was demonstrated in a recently published study, 
the results of which are summarized along with other studies 
above.86 In this particular study, 73 patients received rhAPC 
at two university hospitals. Twenty of these 73 patients (27%) 
met package criteria for having either a “warning” (n = 19) 
or a “contraindication” (n = 1) for use based on bleeding 
risk. Overall, nine of the 73 patients (12%) experienced 
a serious bleeding event. However, seven of these events 
occurred in patients identified as having a baseline bleeding 
risk vs just two in patients without such a risk. In other 
words, seven of the 20 patients with a baseline bleeding 
risk (35%) had a serious bleeding event when treated with 
rhAPC. Multivariate analysis also revealed an association 
between bleeding warnings and increased mortality with 
rhAPC therapy (odds ratio 5.2; p = 0.0098). The small size 
of this study does raise concern regarding possible sampling 
error. However, these findings agree with those from another 
study also summarized above, in which the risk of bleeding 
with rhAPC increased in patients with multiple organ 
failure and a relative contraindication to rhAPC therapy.99 
Perhaps more striking, these and other trials found that use 
of rhAPC in the presence of bleeding precautions was quite 
prevalent.86,97,99
The FDA has issued several warning about bleeding risk 
in particular subgroups. Ongoing concerns regarding such 
risks have prompted the FDA to initiate an additional safety 
review of clinical use of rhAPC. This review is ongoing.108 
Table 3 Summary of adverse events in uncontrolled studies
Patient with SBE (%) Patients with ICH (%)
Author Total number of patients Infusion Full study period Infusion Full study period
Tanzi102 599 NAa 28 (4.7) NA 3 (0.5)
Vincent73b 2378 85 (3.6) 165 (6.5) 14 (0.6) 33 (1.4)
Kübler100 302 NA 5 (1.7) NA NA
Spriet101 23 1 (4.3) 1 (4.3) NA NA
Levi87 1935 202 (2.3) 88 (4.6) 6 (0.3) 17 (0.9)
Kanji99 261 19 (7.3) 25 (10) 10 (0.4) NA
Bertolini97 668 15 (4.6) NA NA 6 (0.9)
Wheeler104 274 11 (4) 12 (4.4) 1 (0.4) 1 (0.4)
Ridley88 351 NA 8 (2.3) NA 2 (0.6)
Vincent90 436 NA NA NA NA
Rowan89 1079 NA 80 (6) NA 7 (0.5)
Taylor103 99 NA 7 (7) 0 (0) 0 (0)
Gentry86 73 7 (10) 9 (12.3) NA 2 (2.7)
Decruyenaere98 97 5 (5.2) NA 1 (1%) NA
Notes: aNot available; bBolded studies were provided support by the manufacturer of rhAPC (eli Lilly and Company).
Abbreviations: iCH, intracerebral hemorrhage; SBe, serious bleeding events. Means ± standard deviation.Biologics: Targets & Therapy 2009:3 402
Altaweel et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The EMEA has also requested that an additional controlled 
trial of rhAPC be conducted in the patient group for which it 
is now prescribed. As a result of these concerns, two additional 
randomized controlled trials are underway in septic patients 
with persistent shock. Until the results from these trials are 
available for guidance, physicians must still decide which 
patients should be considered for treatment with rhAPC.109–111 
In light of data from studies such as the ones outlined here, 
one approach for increasing the safety of rhAPC without 
compromising any potential efficacy is not to administer it to 
any septic patients with baseline bleeding risks, which effec-
tively changes the labeled warnings to contraindications.
Conclusions
Treatment with rhAPC may have several potential beneficial 
effects during sepsis and septic shock. In addition to the 
inhibition of injurious thrombotic events, increasing data 
suggests rhAPC could have important anti-inflammatory 
effects via its interaction with EPCR and PAR-1. Despite its 
potential benefit in sepsis, the apparent efficacy of rhAPC 
in PROWESS has not been reproduced in subsequent trials, 
while an increased risk of bleeding has been confirmed in 
controlled trials and documented at even higher rates in 
clinical use. Such a complication is of even greater concern 
for patients as fragile as those with sepsis and septic shock. 
Thus, whether the potential benefits of this treatment outweigh 
its risks in septic patients during clinical use is not clear. 
Comparing uncontrolled clinical experience to the original 
PROWESS trial is confounded however by differences in the 
way rhAPC may have been administered in the two settings 
(eg, delayed treatment in clinical use) and in the patients 
receiving rhAPC (eg, increased bleeding precautions during 
clinical use).
Preclinical studies now suggest that rhAPC, besides 
having anticoagulant effects, may have anti-inflammatory, 
antiapoptotic and endothelial effects which could also be 
beneficial during sepsis. Why such an agent has not shown 
more consistent benefit since the original PROWESS trial 
is not clear. One possibility as we have outlined is that the 
risks associated with the agent may outweigh its benefits 
in particular subgroups that still require clearer definition. 
In this respect, however, the experience with rhAPC is not 
Figure 5 Comparison of the incidence of serious bleeding events (upper panel) and intracerebral hemorrhage (lower panel) during drug infusion or up until intensive care 
unit or hospital discharge in patients receiving rhAPC in PrOweSS to those in subsequent uncontrolled trials. in almost all uncontrolled studies, these incidences were greater 
than in the PrOweSS trial.
Notes: aiCU stay; bHospital stay.
Abbreviation: iCU, intensive care unit; rhAPC, recombinant human activated protein C.
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dissimilar from other immunomodulators which showed 
benefit in repeated preclinical sepsis studies but not in 
clinical ones.112
The PROWESS trial and the experience with rhAPC in 
sepsis presents issues similar to ones presented by initial 
trials of early goal-directed therapy and intensive insulin 
therapy.113 In each case, despite the highly significant 
survival effects reported with treatment, questions arose 
about trial design and conduct that suggested confirmatory 
trials were warranted. Despite these questions and possibly 
because of the high mortality associated with sepsis, each of 
these therapies was rapidly introduced clinically. However, 
subsequent experience with each of these agents resulted 
in more rather than fewer questions. In fact subsequent 
controlled trials with intensive insulin have highlighted the 
potential harm associated with this type of therapy in sepsis 
and the critically ill.114 This experience emphasizes the weak-
ness of a single RCT. This weakness may relate to the fact 
that patients with sepsis are a heterogeneous group with a 
high overall mortality rate. Furthermore, the pathogenesis 
of sepsis is poorly understood. While the RCT minimizes 
selection bias, it remains a single experiment and does not 
guarantee external validity for a syndrome as complex and 
lethal as sepsis. As such, reproducible and highly consistent 
evidence of benefit in a clearly defined and easily identifiable 
group of patients is important before conferring regulatory 
approval or changing clinical practice.
Controlled trials are presently underway to better define 
the benefit-to-risk ratio of rhAPC in sepsis. Until such trials 
are complete, physicians employing rhAPC must care-
fully select those patients receiving it. One potential way 
to optimize the benefit-to-risk ratio with rhAPC would be 
to administer treatment clinically employing similar inclu-
sion and exclusion criteria to those used during the original 
PROWESS trial.
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